Amgen, Servier sign licensing deal for cardiovascular drug

07/10/2013 | American City Business Journals · Drug Store News

Servier granted Amgen rights to market its heart failure and angina drug Procoralan, or ivabradine, in the U.S. as well as an exclusive option to develop and market its experimental heart failure drug S38844. Servier could get $50 million upfront plus milestone fees and sales royalties for ivabradine, which is already cleared in Europe. The deal also gives Servier rights to commercialize Amgen's heart failure drug candidate omecamtiv mecarbil in Europe.

View Full Article in:

American City Business Journals · Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC